<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0157129</article-id>
<article-id pub-id-type="publisher-id">PONE-D-15-48399</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cerebrovascular diseases</subject><subj-group><subject>Stroke</subject><subj-group><subject>Ischemic stroke</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Vascular medicine</subject><subj-group><subject>Stroke</subject><subj-group><subject>Ischemic stroke</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social sciences</subject><subj-group><subject>Economics</subject><subj-group><subject>Economic analysis</subject><subj-group><subject>Cost-effectiveness analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Hemorrhage</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Signs and symptoms</subject><subj-group><subject>Hemorrhage</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Vascular medicine</subject><subj-group><subject>Hemorrhage</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Geographical locations</subject><subj-group><subject>Asia</subject><subj-group><subject>Hong Kong</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Arrhythmia</subject><subj-group><subject>Atrial fibrillation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Neurology</subject><subj-group><subject>Cerebrovascular diseases</subject><subj-group><subject>Stroke</subject><subj-group><subject>Hemorrhagic stroke</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Vascular medicine</subject><subj-group><subject>Stroke</subject><subj-group><subject>Hemorrhagic stroke</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Anticoagulants</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and places</subject><subj-group><subject>Population groupings</subject><subj-group><subject>Ethnicities</subject><subj-group><subject>Chinese people</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses</article-title>
<alt-title alt-title-type="running-head">Cost-Effectiveness Analysis of Apixaban vs Warfarin</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Li</surname>
<given-names>Xue</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Tse</surname>
<given-names>Vicki C.</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Lau</surname>
<given-names>Wallis C. Y.</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Cheung</surname>
<given-names>Bernard M. Y.</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Lip</surname>
<given-names>Gregory Y. H.</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Wong</surname>
<given-names>Ian C. K.</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Chan</surname>
<given-names>Esther W.</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong SAR, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Bishopric</surname>
<given-names>Nanette H</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>University of Miami School of Medicine, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>EWC received financial support from Janssen, a division of Johnson and Johnson, Bristol Myers Squibb, Pfizer and Eisai; The Pharmaceutical Society of Hong Kong; The University of Hong Kong; Early Career Scheme and the General Research Fund, Research Grants Council, Hong Kong. There are no patents, products in development, or marketed products to declare. This does not alter the authorsâ€™ adherence to PLOS ONE policies on sharing data and materials.</p>
</fn>
<fn fn-type="con" id="contrib001">
<p>Conceived and designed the experiments: EWC XL IW. Performed the experiments: XL WL. Analyzed the data: XL WL. Contributed reagents/materials/analysis tools: EWC IW. Wrote the paper: XL VT WL BC GL IW EWC.</p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">ewchan@hku.hk</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>6</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>11</volume>
<issue>6</issue>
<elocation-id>e0157129</elocation-id>
<history>
<date date-type="received">
<day>5</day>
<month>11</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>25</day>
<month>5</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Li et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0157129"/>
<abstract>
<sec id="sec001">
<title>Objectives</title>
<p>Many of the cost-effectiveness analyses of apixaban against warfarin focused on Western populations but Asian evidence remains less clear. The present study aims to evaluate the cost-effectiveness of apixaban against warfarin in Chinese patients with non-valvular atrial fibrillation (NVAF) from a public institutional perspective in Hong Kong.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>We used a Markov model incorporating 12 health state transitions, and simulated the disease progression of NVAF in 1,000 hypothetical patients treated with apixaban/warfarin. Risks of clinical events were based on the ARISTOTLE trial and were adjusted with local International Normalized Ratio control, defined as the time in therapeutic range. Real-life input for the model, including patientsâ€™ demographics and clinical profiles, post-event treatment patterns, and healthcare costs, were determined by a retrospective cohort of 40,569 incident patients retrieved from a Hong Kong-wide electronic medical database. Main outcome measurements included numbers of thromboembolic and bleeding events, life years, quality-adjusted life years (QALYs) and direct healthcare cost. When comparing apixaban and warfarin, treatment with incremental cost-effectiveness ratio (ICER) less than one local GDP per capita (USD 33,534 in 2014) was defined to be cost-effective.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>In the lifetime simulation, fewer numbers of events were estimated for the apixaban group, resulting in reduced event-related direct medical costs. The estimated ICER of apixaban was USD 7,057 per QALY at base-case analysis and ranged from USD 1,061 to 14,867 per QALY under the 116 tested scenarios in deterministic sensitivity analysis. While in probabilistic sensitivity analysis, the probability of apixaban being the cost-effective alternative to warfarin was 96% and 98% at a willingness to pay threshold of USD 33,534 and 100,602 per QALY, respectively.</p>
</sec>
<sec id="sec004">
<title>Conclusions</title>
<p>Apixaban is likely to be a cost-effective alternative to warfarin for stroke prophylaxis in Chinese patients with NVAF in Hong Kong.</p>
</sec>
</abstract>
<funding-group>
<funding-statement>This study was supported by a grant from Bristol Myers Squibb and Pfizer (reference number: 260007295). EWC received financial support from Janssen, a division of Johnson and Johnson, Bristol Myers Squibb, Pfizer and Eisai; The Pharmaceutical Society of Hong Kong; The University of Hong Kong; Early Career Scheme and the General Research Fund, Research Grants Council, Hong Kong. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="4"/>
<table-count count="3"/>
<page-count count="15"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Non-valvular atrial fibrillation (NVAF), the most common sustained cardiac arrhythmia, affects 1â€“2% of the general population worldwide and its prevalence increases with age [<xref ref-type="bibr" rid="pone.0157129.ref001">1</xref>, <xref ref-type="bibr" rid="pone.0157129.ref002">2</xref>]. As one of the risk factors for stroke and systemic embolism, NVAF is associated with long-term morbidity, impaired quality of life, mortality and considerable financial burden. The healthcare cost for patients with NVAF is estimated to increase 1.6â€“3.1 fold after the occurrence of thromboembolic events, particularly in the first three years [<xref ref-type="bibr" rid="pone.0157129.ref003">3</xref>]. Therefore, stroke prevention in patients with NVAF is important from both individual and societal perspectives.</p>
<p>Long-term anticoagulation management is required for stroke prophylaxis in patients with NVAF. Traditionally, warfarin (a vitamin K antagonist) has been the most commonly used anticoagulant [<xref ref-type="bibr" rid="pone.0157129.ref004">4</xref>]. However warfarin poses challenges with respect to clinical management due to its narrow therapeutic range and drug metabolism affected by multiple factors such as genetic variables, diet and drug interactions[<xref ref-type="bibr" rid="pone.0157129.ref005">5</xref>]. Apixaban (a novel direct factor Xa inhibitor) was therefore developed as an alternate anticoagulant. A multinational trial of ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) demonstrated apixaban to be superior to warfarin in prevention of ischaemic stroke (21% reduction), bleeding (31% reduction) and mortality (11% reduction) without the need for monitoring [<xref ref-type="bibr" rid="pone.0157129.ref006">6</xref>]. Recent subgroup analysis of the landmark trial showed consistent protective effect of apixaban on stroke, bleeding and mortality in East Asian and non-East Asian patients [<xref ref-type="bibr" rid="pone.0157129.ref007">7</xref>].</p>
<p>In addition to improved clinical efficacy and safety compared against standard treatment, cost-effectiveness is also an important consideration for new treatments in the setting of increased healthcare costs globally. Apixaban has been found to be cost-effective against warfarin in Europe [<xref ref-type="bibr" rid="pone.0157129.ref008">8</xref>â€“<xref ref-type="bibr" rid="pone.0157129.ref010">10</xref>], Australia [<xref ref-type="bibr" rid="pone.0157129.ref011">11</xref>] and USA [<xref ref-type="bibr" rid="pone.0157129.ref012">12</xref>]. Notably, the current CE literature all focused on Western populations. Although Asians and Westerns share similar risk factor profiles, they might not be the same due to more history of stroke, increased tendency to bleed and suboptimal international normalised ratio (INR) control when treated with warfarin [<xref ref-type="bibr" rid="pone.0157129.ref013">13</xref>]. These factors may have an impact on the cost-effective manner of anticoagulation therapies. Hence, it is important to incorporate local data to evaluate CE in the Asian population. The objective of the present study is to evaluate the cost-effectiveness of apixaban versus warfarin for stroke prophylaxis in Chinese patients with NVAF, from the public institutional perspective in Hong Kong.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Methods</title>
<p>The research protocol was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster, Hong Kong. No written informed consent was obtained from patients for their clinical records to be used in this study, due to this is a retrospective study based on electronic medical database. All of the patient records/information was anonymized and de-identified prior to analysis.</p>
<sec id="sec007">
<title>Overview</title>
<p>This study compares the cost-effectiveness of apixaban against warfarin in Chinese patients with NVAF using a Markov model. Data sources and the retrieval procedure are illustrated in <bold><xref ref-type="fig" rid="pone.0157129.g001">Fig 1</xref>.</bold> Lifetime cost and health outcomes were estimated from Markov cohort simulations. A retrospective cohort study was conducted to obtain real-life data for the model inputs. Clinical event risks were based on the ARISTOTLE trial [<xref ref-type="bibr" rid="pone.0157129.ref006">6</xref>] and incorporated by local INR control. Where local data were not available, data retrieved from comprehensive literature review and expert opinion were used. Baseline inputs are listed in <bold>Tables A and B in <xref ref-type="supplementary-material" rid="pone.0157129.s001">S1 File</xref></bold>. Model inputs were entered, cross-checked and analysed independently by two researchers.</p>
<fig id="pone.0157129.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0157129.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Data sources for Markov cohort simulation.</title>
<p>ARISTOTLE: Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; CDARS: Clinical Data Analysis and Reporting System of Hong Kong; NVAF: non-valvular atrial fibrillation.</p>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0157129.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec008">
<title>Model</title>
<p>A previously developed Microsoft Excel Markov model incorporating 12 health states was adapted to simulate lifetime disease progression in 1,000 patients treated by apixaban (5mg BID) or warfarin (any strength)[<xref ref-type="bibr" rid="pone.0157129.ref014">14</xref>]. The health states modeled include NVAF, ischaemic stroke, systemic embolism, myocardial infarction, bleeding and death. A simplified schematic representation of the model structure and the health states transitions starting from NVAF are shown in <bold>Figures A and B in <xref ref-type="supplementary-material" rid="pone.0157129.s001">S1 File</xref></bold>. A detailed description of the model can be found in previous publications [<xref ref-type="bibr" rid="pone.0157129.ref008">8</xref>, <xref ref-type="bibr" rid="pone.0157129.ref010">10</xref>, <xref ref-type="bibr" rid="pone.0157129.ref015">15</xref>]. For each treatment group, the number of events in each health state, life years (LYs), quality-adjusted life years (QALYs) and direct healthcare cost were calculated at the end of each model cycle and accumulated across lifetime.</p>
</sec>
<sec id="sec009">
<title>Population</title>
<p>The target population of the model are patients with NVAF who are suitable for warfarin therapy. Patient profiles were determined by a retrospective cohort analysis of incident patients with NVAF in the Clinical Data Analysis and Reporting System (CDARS). In brief, CDARS is an electronic medical database in Hong Kong that covers a population of over 7 million utilising public healthcare services and accounts for 80% of inpatient records in the territory [<xref ref-type="bibr" rid="pone.0157129.ref016">16</xref>]. De-identified electronic patientsâ€™ records, including demographics, diagnoses, procedures, drug descriptions, laboratory tests and date of consultation, hospital admission and discharge, were all imported to CDARS for audit and research purposes.</p>
<p>At the time of the study, CDARS was unable to identify patients with NVAF directly. Target patients were identified by first retrieving patients with documented diagnosis of atrial fibrillation from Jan 1st 2010 to Dec 31st 2013 using ICD-9 diagnosis codes (<bold>Table C in <xref ref-type="supplementary-material" rid="pone.0157129.s001">S1 File</xref></bold> for ICD-9 codes used). Among these patients, those with diagnoses of valvular heart disease, hyperthyroidism or had undergone valvular replacement surgery within 1 year prior to the index date were further excluded according to corresponding ICD-9 codes. The follow-up of each patient was commenced from the index date until the occurrence of any clinical events, death or July 31<sup>st</sup> 2014, whichever came first. This resulted in the identification of 40,569 eligible patients with 76,196 patient-years of follow-up. The key demographic and clinical profiles of these patients are shown in <bold><xref ref-type="table" rid="pone.0157129.t001">Table 1</xref>.</bold></p>
<table-wrap id="pone.0157129.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0157129.t001</object-id>
<label>Table 1</label> <caption><title>Demographic and clinical profiles of patients with NVAF in CDARS 2010â€“13.</title></caption>
<alternatives>
<graphic id="pone.0157129.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0157129.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Characteristics</th>
<th align="left"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold><italic>Sample size</italic></bold></td>
<td align="left"><bold>40,569</bold></td>
</tr>
<tr>
<td align="left"><italic>Demographics</italic></td>
<td align="left"/>
</tr>
<tr>
<td align="left">Age [median (interquartile range)]</td>
<td align="left">78.9 (69.7â€“85.6)</td>
</tr>
<tr>
<td align="left">Female sex (%)</td>
<td align="left">50.4</td>
</tr>
<tr>
<td align="left"><bold><italic>Medical history</italic></bold></td>
<td align="left"/>
</tr>
<tr>
<td align="left">Prior myocardial infarction (%)</td>
<td align="left">9.2</td>
</tr>
<tr>
<td align="left">Prior clinically relevant bleeding (%)</td>
<td align="left">19.3</td>
</tr>
<tr>
<td align="left">Prior stroke, transient ischaemic attack, or systemic embolism (%)</td>
<td align="left">20.6</td>
</tr>
<tr>
<td align="left">Heart failure or reduced left ventricular ejection fraction (%)</td>
<td align="left">25.3</td>
</tr>
<tr>
<td align="left">Diabetes (%)</td>
<td align="left">22.2</td>
</tr>
<tr>
<td align="left">Hypertension requiring treatment (%)</td>
<td align="left">76.0</td>
</tr>
<tr>
<td align="left"><bold><italic>CHADS</italic></bold><sub><bold><italic>2</italic></bold></sub> <bold><italic>score</italic></bold><xref ref-type="table-fn" rid="t001fn001">*</xref></td>
<td align="left"/>
</tr>
<tr>
<td align="left">Distribution (%)</td>
<td align="left"/>
</tr>
<tr>
<td align="left">0â€“1</td>
<td align="left">41.6</td>
</tr>
<tr>
<td align="left">2</td>
<td align="left">24.0</td>
</tr>
<tr>
<td align="left">â‰¥3</td>
<td align="left">34.4</td>
</tr>
<tr>
<td align="left">Mean (SD)</td>
<td align="left">2.0 (1.5)</td>
</tr>
<tr>
<td align="left"><bold><italic>TTR distribution (%)</italic></bold> <xref ref-type="table-fn" rid="t001fn002"><sup><bold><italic>â€ </italic></bold></sup></xref></td>
<td align="left"/>
</tr>
<tr>
<td align="left">TTR &lt; 52.38%</td>
<td align="left">61.3</td>
</tr>
<tr>
<td align="left">52.38% â‰¤ TTR &lt; 66.02%</td>
<td align="left">18.1</td>
</tr>
<tr>
<td align="left">66.02% â‰¤ TTR &lt; 76.51%</td>
<td align="left">9.0</td>
</tr>
<tr>
<td align="left">TTR â‰¥ 76.51%</td>
<td align="left">11.6</td>
</tr>
<tr>
<td align="left"><bold><italic>Anticoagulation management</italic>, <italic>monitoring and routine care</italic></bold></td>
<td align="left"/>
</tr>
<tr>
<td align="left">Frequency of INR monitoring (number/month)</td>
<td align="left">1.0</td>
</tr>
<tr>
<td align="left">Patients experiencing dyspepsia whilst on warfarin (%)</td>
<td align="left">0.4</td>
</tr>
<tr>
<td align="left">Patients requiring annual renal monitoring while on warfarin (%)</td>
<td align="left">29.7</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>* CHADS<sub>2</sub>: congestive heart failure, hypertension, ageâ‰¥75 years, diabetes mellitus and stroke</p></fn>
<fn id="t001fn002"><p>â€  TTR: time in therapeutic range estimated using the Rosendaal method.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec010">
<title>Risk of clinical events</title>
<p>The clinical event rates of apixaban and warfarin were obtained from the ARISTOTLE trial [<xref ref-type="bibr" rid="pone.0157129.ref006">6</xref>]. As the risk of ischaemic stroke and bleeding associated with warfarin are highly dependent on the quality of INR control [<xref ref-type="bibr" rid="pone.0157129.ref017">17</xref>, <xref ref-type="bibr" rid="pone.0157129.ref018">18</xref>], the model was developed to adjust the event risks by local INR control. Time in therapeutic range (TTR) distribution was defined as the indicator of INR control and collected from the CDARS retrospective cohort study.</p>
</sec>
<sec id="sec011">
<title>Fatality and mortality</title>
<p>For thromboembolic and bleeding events, annual case-fatality rates were estimated from the CDARS retrospective cohort study. All-cause mortality was modelled based on life tables in the general population, adjusting by age, gender and the occurrence of NVAF and relevant co-morbidities.</p>
</sec>
<sec id="sec012">
<title>Anticoagulation management</title>
<p>Healthcare resource consumption regarding anticoagulation management was reflected by the frequency of routine care and monitoring visits, proportion of patients experiencing dyspepsia and proportion of patients requiring annual renal monitoring whilst on treatment from the CDARS retrospective cohort (<bold>Table A in <xref ref-type="supplementary-material" rid="pone.0157129.s001">S1 File</xref></bold>).</p>
</sec>
<sec id="sec013">
<title>Treatment pattern post-events</title>
<p>Treatment patterns post-event were determined from the CDARS retrospective cohort study, published literature or expert opinion wherever appropriate (<bold>Table A in <xref ref-type="supplementary-material" rid="pone.0157129.s001">S1 File</xref></bold>). Following all bleeding events, a certain number of patients were assumed to switch to aspirin as second line treatment. The rate of treatment switch (Â± 90 days of the event index date) was determined by retrieving prescription records from CDARS and literature. The remaining patients were modelled to have their original treatment interrupted for 6 weeks then restarted [<xref ref-type="bibr" rid="pone.0157129.ref019">19</xref>] (i.e. as shown in <bold>Table A in <xref ref-type="supplementary-material" rid="pone.0157129.s001">S1 File</xref></bold>, post intracranial haemorrhage, 44% of patients switched to aspirin and the remaining 56% discontinued their original treatment temporarily and restarted the same treatment 6 weeks later). [<xref ref-type="bibr" rid="pone.0157129.ref020">20</xref>]Following occurrence of ischaemic stroke and systemic embolism, all patients were assumed to continue the original treatment as advised by experts.</p>
</sec>
<sec id="sec014">
<title>Utility</title>
<p>Utility for NVAF was adopted from Ho et al [<xref ref-type="bibr" rid="pone.0157129.ref021">21</xref>], which was the only study to assess the health utility of Hong Kong patients with NVAF on oral anticoagulants. Due to the absence of population-specific utility estimations, a UK-based utility catalogue was adopted for other health states [<xref ref-type="bibr" rid="pone.0157129.ref022">22</xref>]. Marginal disutility was assumed to be associated with INR monitoring when treated with warfarin due to the required blood test [<xref ref-type="bibr" rid="pone.0157129.ref023">23</xref>]. All utility inputs were discounted at 3.5% per year and detailed in <bold>Table B in <xref ref-type="supplementary-material" rid="pone.0157129.s001">S1 File</xref></bold>.</p>
</sec>
<sec id="sec015">
<title>Cost</title>
<p>The analysis was conducted from a public institutional perspective in Hong Kong so only direct medical costs were considered. Costs are presented to the value of US dollars in 2014 (1 USD to 7.75 HKD) and discounted at 3.5% per year according to cost-effectiveness analyses (CEA) guideline [<xref ref-type="bibr" rid="pone.0157129.ref024">24</xref>].</p>
<p>The total cost components are outlined in <bold>Table B in <xref ref-type="supplementary-material" rid="pone.0157129.s001">S1 File</xref></bold>. Daily drug costs for warfarin and apixaban were based on local retail prices (internal communication with Bristol-Myers Squibb, Hong Kong, November 2014). Annual monitoring and management costs were determined by multiplying the cost for blood and renal tests per visit by number of clinical visits per patient from the CDARS retrospective cohort. Similarly, acute care costs associated with clinical events were calculated by multiplying daily inpatient charges in public hospital [<xref ref-type="bibr" rid="pone.0157129.ref025">25</xref>, <xref ref-type="bibr" rid="pone.0157129.ref026">26</xref>] by the average hospital length of stay estimated from the same cohort. Long-term care costs include medication costs only.</p>
</sec>
<sec id="sec016">
<title>Analyses</title>
<p>We compared the cost-effectiveness of apixaban versus warfarin by assessing the differences in lifetime cost and clinical benefits. Base-case analysis was performed based on model inputs described earlier. Treatment with incremental cost-effective ratio (ICER) less than the willingness-to-pay (WTP) threshold of one local GDP per capita (USD 33,534 in 2014 [<xref ref-type="bibr" rid="pone.0157129.ref027">27</xref>]) for each QALY gained was considered a cost-effective alternative as recommended by the WHO-CHOICE guideline [<xref ref-type="bibr" rid="pone.0157129.ref028">28</xref>].</p>
<p>The effect of uncertainties in the base-case analysis was evaluated by deterministic and probabilistic sensitivity analyses (SA). In deterministic SA, each of the 116 input parameters varied from a predefined range (95% CI or SD, as listed in <bold>Tables A and B in <xref ref-type="supplementary-material" rid="pone.0157129.s001">S1 File</xref></bold>) while all the others were constant to project its effect on ICER. All tested parameters were ranked according to ICER variation and the top 15 most influential parameters were presented in Tornado diagrams.</p>
<p>In probabilistic SA, probability distributions were assigned to each parameter (gamma distribution to event rates, beta distribution to utilities and log-normal distribution to cost) and varied simultaneously in 2,000 iterations for the pair-wise comparisons. The cost and health outcomes were further assessed using cost-effectiveness acceptability curves (CEACs). Two willingness-to-pay (WTP) thresholds, one-time and three-times of local GDP per capita (USD 33,534 and USD 100,602 in 2014 [<xref ref-type="bibr" rid="pone.0157129.ref027">27</xref>]) were applied to explore the proportion of acceptable trials for each treatment.</p>
</sec>
</sec>
<sec id="sec017" sec-type="results">
<title>Results</title>
<sec id="sec018">
<title>Base-case analysis</title>
<p>From a cohort of 1,000 patients over a lifetime, the use of apixaban was predicted to result in 116 fewer NVAF-related events (12 fewer ischaemic strokes, 15 fewer haemorrhagic strokes, 12 fewer other intracranial haemorrhages, 25 fewer other major bleeds, 2 fewer myocardial infarctions) and 31 fewer event-related deaths than patients treated with warfarin in the base-case analysis (<bold><xref ref-type="table" rid="pone.0157129.t002">Table 2</xref></bold>). Compared with warfarin, 36 patients need to be treated with apixaban to avoid one additional stroke, and apixaban is the dominant treatment in reducing bleeding events.</p>
<table-wrap id="pone.0157129.t002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0157129.t002</object-id>
<label>Table 2</label> <caption><title>Health and cost outcome estimations in base-case analysis.</title></caption>
<alternatives>
<graphic id="pone.0157129.t002g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0157129.t002" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left"/>
<th align="left">Apixaban</th>
<th align="left">Warfarin</th>
<th align="left">Difference (apixabanâ€“warfarin)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left"><bold>Number of events (per cohort of 1000)</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Â Â Â Â Ischaemic stroke</td>
<td align="left">179</td>
<td align="left">191</td>
<td align="left">-12</td>
</tr>
<tr>
<td align="left">Â Â Â Â Haemorrhagic stroke</td>
<td align="left">21</td>
<td align="left">36</td>
<td align="left">-15</td>
</tr>
<tr>
<td align="left">Â Â Â Â Systemic embolism</td>
<td align="left">17</td>
<td align="left">18</td>
<td align="left">-1</td>
</tr>
<tr>
<td align="left">Â Â Â Â Other intracranial haemorrhage</td>
<td align="left">9</td>
<td align="left">21</td>
<td align="left">-12</td>
</tr>
<tr>
<td align="left">Â Â Â Â Other major bleeds</td>
<td align="left">106</td>
<td align="left">131</td>
<td align="left">-25</td>
</tr>
<tr>
<td align="left">Â Â Â Â Clinically relevant non-major bleeds</td>
<td align="left">190</td>
<td align="left">239</td>
<td align="left">-49</td>
</tr>
<tr>
<td align="left">Â Â Â Â Myocardial infarction</td>
<td align="left">62</td>
<td align="left">64</td>
<td align="left">-2</td>
</tr>
<tr>
<td align="left">Â Â Â Â <italic>Total number of events</italic></td>
<td align="left"><italic>584</italic></td>
<td align="left"><italic>700</italic></td>
<td align="left"><italic>-116</italic></td>
</tr>
<tr>
<td align="left"><bold>Death (per cohort of 1000)</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Â Â Â Â Event related death</td>
<td align="left">268</td>
<td align="left">299</td>
<td align="left">-31</td>
</tr>
<tr>
<td align="left">Â Â Â Â Other deaths</td>
<td align="left">732</td>
<td align="left">701</td>
<td align="left">31</td>
</tr>
<tr>
<td align="left"><bold>Health outcome (per patient)</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Â Â Â Â Life years</td>
<td align="left">6.84</td>
<td align="left">6.67</td>
<td align="left">0.17</td>
</tr>
<tr>
<td align="left">Â Â Â Â Quality adjusted life years</td>
<td align="left">5.06</td>
<td align="left">4.88</td>
<td align="left">0.18</td>
</tr>
<tr>
<td align="left"><bold>Cost components (USD per patient)</bold></td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Anticoagulant</td>
<td align="left">3,239</td>
<td align="left">379</td>
<td align="left">2860</td>
</tr>
<tr>
<td align="left">Monitoring and management</td>
<td align="left">64</td>
<td align="left">885</td>
<td align="left">-821</td>
</tr>
<tr>
<td align="left">Clinical events</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Â Â Â Â Ischaemic stroke</td>
<td align="left">2,872</td>
<td align="left">3,121</td>
<td align="left">-249</td>
</tr>
<tr>
<td align="left">Â Â Â Â Haemorrhagic stroke</td>
<td align="left">317</td>
<td align="left">560</td>
<td align="left">-243</td>
</tr>
<tr>
<td align="left">Â Â Â Â Systemic embolism</td>
<td align="left">319</td>
<td align="left">330</td>
<td align="left">-11</td>
</tr>
<tr>
<td align="left">Â Â Â Â Other intracranial haemorrhage</td>
<td align="left">31</td>
<td align="left">75</td>
<td align="left">-44</td>
</tr>
<tr>
<td align="left">Â Â Â Â Other major bleeds</td>
<td align="left">503</td>
<td align="left">661</td>
<td align="left">-158</td>
</tr>
<tr>
<td align="left">Â Â Â Â Clinically relevant non-major bleeds</td>
<td align="left">677</td>
<td align="left">869</td>
<td align="left">-192</td>
</tr>
<tr>
<td align="left">Â Â Â Â Myocardial infarction</td>
<td align="left">376</td>
<td align="left">393</td>
<td align="left">-17</td>
</tr>
<tr>
<td align="left">Â Â Â Â Other cardiovascular hospitalisation</td>
<td align="left">3,928</td>
<td align="left">3,825</td>
<td align="left">103</td>
</tr>
<tr>
<td align="left">Â Â Â Â Total event cost</td>
<td align="left">9,023</td>
<td align="left">9,834</td>
<td align="left">-811</td>
</tr>
<tr>
<td align="left"><italic>Total lifetime cost</italic></td>
<td align="left"><italic>12</italic>,<italic>326</italic></td>
<td align="left"><italic>11</italic>,<italic>098</italic></td>
<td align="left"><italic>1</italic>,<italic>228</italic></td>
</tr>
</tbody>
</table>
</alternatives>
</table-wrap>
<p>The cost of treating one patient with apixaban was USD 1,228 more than warfarin (<bold><xref ref-type="table" rid="pone.0157129.t002">Table 2</xref></bold>). This was predominantly attributed to the higher drug price of apixaban, in contrast to lower costs related to management, monitoring and clinical events. Compared with warfarin, the net cost, net health benefits and incremental cost-effective ratios of apixaban were detailed in <bold><xref ref-type="table" rid="pone.0157129.t003">Table 3</xref>.</bold></p>
<table-wrap id="pone.0157129.t003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0157129.t003</object-id>
<label>Table 3</label> <caption><title>Base-case cost-effectiveness analysis.</title></caption>
<alternatives>
<graphic id="pone.0157129.t003g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0157129.t003" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="left">Evaluated items</th>
<th align="left">Apixaban vs. Warfarin</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Â Â Â Â Net cost (USD per patient)</td>
<td align="left">1,228</td>
</tr>
<tr>
<td align="left">Â Â Â Â Net QALYs (per patient)</td>
<td align="left">0.18</td>
</tr>
<tr>
<td align="left">Â Â Â Â Net life-years (per patient)</td>
<td align="left">0.17</td>
</tr>
<tr>
<td align="left">Â Â Â Â Incremental cost per QALY gained (USD/QALY)</td>
<td align="left">7,057</td>
</tr>
<tr>
<td align="left">Â Â Â Â Incremental cost per life year gained (USD/LY)</td>
<td align="left">7,181</td>
</tr>
<tr>
<td align="left">Â Â Â Â Incremental cost per stroke avoided (USD/stroke avoided)<xref ref-type="table-fn" rid="t003fn001">*</xref></td>
<td align="left">45,481</td>
</tr>
<tr>
<td align="left">Â Â Â Â Incremental cost per bleed avoided (USD/bleed avoided) <xref ref-type="table-fn" rid="t003fn002"><sup><bold><italic>â€ </italic></bold></sup></xref></td>
<td align="left">23,615</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t003fn001"><p>* Stroke included first-ever and recurrent ischaemic and haemorrhagic strokes</p></fn>
<fn id="t003fn002"><p><bold><italic>â€ </italic></bold> Bleed included first-ever and recurrent haemorrhagic stroke, other intracranial haemorrhage and other major bleeds.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec019">
<title>Deterministic sensitivity analyses</title>
<p>As illustrated in <bold><xref ref-type="fig" rid="pone.0157129.g002">Fig 2</xref></bold>, tested model inputs had limited impact on the ICER. The ICER ranged from USD 1,061 to 14,867 per QALY gained under 116 tested scenarios, all of which were within the threshold of USD 33,534 per QALY (one local GDP per capita). Uncertainties in drug costs, the risk of cardiovascular hospitalisation for both treatments, risk of ischaemic stroke for apixaban and risk of intracranial haemorrhage for warfarin had greatest impact on the ICER.</p>
<fig id="pone.0157129.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0157129.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Tornado diagram of apixaban versus warfarin.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0157129.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec020">
<title>Probabilistic sensitivity analyses</title>
<p>The probabilistic sensitivity analysis demonstrated that apixiban is more cost-effective against warfarin over a life-time horizon (<bold><xref ref-type="fig" rid="pone.0157129.g003">Fig 3</xref></bold>). ICER was below the threshold of USD 33,534 per QALY (one local GDP per capita) in 96% of the trials. When the upper range of the WHO threshold of USD 100,602 per QALY gained (three-times of local GDP per capita) was applied, 98% of the trials supported the cost-effectiveness of apixaban.</p>
<fig id="pone.0157129.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0157129.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Probabilistic sensitivity analysis of apxiaban versus warfarin.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0157129.g003" xlink:type="simple"/>
</fig>
<p>The uncertainties in the cost-effective estimates are further summarised in the cost-effectiveness acceptability curve in <bold><xref ref-type="fig" rid="pone.0157129.g004">Fig 4</xref>.</bold> This demonstrates that apixaban was a superior treatment choice representing the maximum net benefit over warfarin, when payers are willing to pay USD 7,500 or above for one QALY gained.</p>
<fig id="pone.0157129.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0157129.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Cost-effectiveness acceptability curves of apixaban and warfarin.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0157129.g004" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec021" sec-type="conclusions">
<title>Discussion</title>
<sec id="sec022">
<title>Summary of findings</title>
<p>In this study, our principal findings were as follows: (i) fewer thromboembolic events were estimated for the apixaban group in the lifetime cohort simulations, resulting in corresponding increased LYs, QALYs and reduced event-related healthcare costs; (ii) compared with warfarin, apixaban presented an ICER of USD 1,061â€“14,867 per QALY gained which is within the common acceptable WTP of one local GDP per capita as recommended by the WHO[<xref ref-type="bibr" rid="pone.0157129.ref028">28</xref>]; (iii) both deterministic and probabilistic sensitivity analyses support the cost-effectiveness of apixaban over a range of uncertainties. This study utilises the strength of CDARS, which collects clinical data in the public healthcare setting across the whole territory. As far as we are aware, this is the only study which utilises real-life, Hong Kong-specific cost, patient demographics and clinical profiles, treatment patterns and case fatality rates to compare the cost-effectiveness of apixaban versus warfarin.</p>
<p>The greater health benefits and cost-effectiveness of apixaban findings in this study are in line with other modeling CE studies conducted in western developed countries [<xref ref-type="bibr" rid="pone.0157129.ref008">8</xref>â€“<xref ref-type="bibr" rid="pone.0157129.ref012">12</xref>]. Lee et al demonstrated apxiaban as a dominant strategy (both cost and life year savings) from the US Medicare perspective [<xref ref-type="bibr" rid="pone.0157129.ref012">12</xref>], while the remaining four studies all found apixaban more cost-effective against warfarin in Australia, Netherlands, Sweden and United Kingdom at ICERs of AUD 13,679[<xref ref-type="bibr" rid="pone.0157129.ref011">11</xref>], EUR 10,576[<xref ref-type="bibr" rid="pone.0157129.ref008">8</xref>], SEK 33,458[<xref ref-type="bibr" rid="pone.0157129.ref009">9</xref>], GBP 11,909[<xref ref-type="bibr" rid="pone.0157129.ref010">10</xref>] per QALY respectively, applying locally relevant WTP thresholds.</p>
</sec>
<sec id="sec023">
<title>Asian data</title>
<p>In light of the widely reported cost-effectiveness of apixaban in Caucasians, evaluation of the Asian population is still limited. However, from a clinical perspective, Asian and Western patients with AF are not necessarily the same. Firstly, among the five components of the CHADS<sub>2</sub> (congestive heart failure, hypertension, ageâ‰¥75 years, diabetes mellitus and stroke) score, similar risk factor profiles were shared, except previous stroke is more prevalent in Asians (29% vs. 18%) [<xref ref-type="bibr" rid="pone.0157129.ref013">13</xref>]. Secondly, stroke risk is higher in Asians when treated with warfarin as reflected in the subgroup analysis of ARISTOTLE trial (3.4% vs. 1.4%) [<xref ref-type="bibr" rid="pone.0157129.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0157129.ref007">7</xref>]. Thirdly, despite a lower INR in general, warfarin users in Asia are more likely to bleed than non-Asians (3.8% vs. 3.0%) [<xref ref-type="bibr" rid="pone.0157129.ref006">6</xref>, <xref ref-type="bibr" rid="pone.0157129.ref007">7</xref>]. Although the mechanism for these differences remains to be determined, they may all challenge the proper use and cost-effectiveness of warfarin and its alternatives in Asia. For the first time, our analysis showed that apixaban is cost-effective in a Chinese population. This is an important ethnic group in Asia with a high prevalence of stroke [<xref ref-type="bibr" rid="pone.0157129.ref029">29</xref>] and rapidly increasing ageing population [<xref ref-type="bibr" rid="pone.0157129.ref030">30</xref>], which highlights the prominence of this study.</p>
</sec>
<sec id="sec024">
<title>Real-life data</title>
<p>Another important differentiator and strength of our study is the use of real-life, local INR control data in our model. It is well documented in the published literature that good INR control, although important for good clinical outcome [<xref ref-type="bibr" rid="pone.0157129.ref031">31</xref>], is unusual in both clinical trial [<xref ref-type="bibr" rid="pone.0157129.ref032">32</xref>] and real-life settings [<xref ref-type="bibr" rid="pone.0157129.ref033">33</xref>]. The ARISTOTLE trial reported that only 50% of warfarin patients have TTR â‰¥ 66.0% [<xref ref-type="bibr" rid="pone.0157129.ref006">6</xref>]. Hong Kong practice is not an exception. Consistent with our findings from the CDARS retrospective cohort study, which found a median TTR of 40.9%, Ho et al also reported unsatisfactory INR control among patients in Hong Kong with similar TTR (median: 38.8%) [<xref ref-type="bibr" rid="pone.0157129.ref033">33</xref>]. As TTR is negatively correlated with bleeding and thromboembolic events [<xref ref-type="bibr" rid="pone.0157129.ref034">34</xref>], suboptimal INR control in real-life may worsen the performance of warfarin [<xref ref-type="bibr" rid="pone.0157129.ref035">35</xref>]. Potential health benefits offered by apixaban may be greater than that in the clinical trial setting for patients with poor TTR [<xref ref-type="bibr" rid="pone.0157129.ref013">13</xref>] when compared to warfarin. By incorporating real-life INR control for event risks adjustment, our study provides a more realistic picture compared to previous studies where the risks were based on clinical trials [<xref ref-type="bibr" rid="pone.0157129.ref011">11</xref>, <xref ref-type="bibr" rid="pone.0157129.ref012">12</xref>] or tested in scenario analyses [<xref ref-type="bibr" rid="pone.0157129.ref009">9</xref>, <xref ref-type="bibr" rid="pone.0157129.ref010">10</xref>].</p>
<p>Of note, variations in healthcare system and services have been well recognised worldwide [<xref ref-type="bibr" rid="pone.0157129.ref036">36</xref>] and this is another key reason why country-specific CEA needs to be conducted. This study summarised local relevant information and will contribute to anticoagulation policy consideration in Hong Kong and other Asian countries with similar healthcare systems.</p>
</sec>
<sec id="sec025">
<title>Limitations</title>
<p>There are limitations in this modeling analysis. Firstly, clinical efficacy and safety parameters were based on the landmark trial with 1.8 years of follow-up. They were assumed to be constant over the lifetime in the model, but might not reflect the long-term performance of treatments in real terms. Secondly, following a major bleeding event, treatment options were limited to switching to aspirin or restarting the original anticoagulant in 6 weeks. In real-life clinical practice, some patients may cease treatment or choose other anticoagulants. However, aspirin is perceived as a safer alternative to oral anticoagulants in the Chinese population [<xref ref-type="bibr" rid="pone.0157129.ref020">20</xref>] given the particular concerns of increased bleeding risk among the Chinese [<xref ref-type="bibr" rid="pone.0157129.ref037">37</xref>â€“<xref ref-type="bibr" rid="pone.0157129.ref040">40</xref>]. As indicated in our previous work [<xref ref-type="bibr" rid="pone.0157129.ref041">41</xref>], more than twice the number of NVAF patients was receiving antiplatelet drugs including aspirin, compared to oral anticoagulants in Hong Kong, despite having a higher risk of stroke (CHADS<sub>2</sub>â‰¥2). In addition, the cut-off point of assessing treatment switch was restrict to 90 days, based on Witt et alâ€™s study on the association of warfarin interruption and gastrointestinal tract bleeding [<xref ref-type="bibr" rid="pone.0157129.ref042">42</xref>]. This may be arbitrary as there are no published guidelines on the optimal anticoagulation approach for those experiencing a thromboembolic event at the time our study was conducted [<xref ref-type="bibr" rid="pone.0157129.ref043">43</xref>]. Thirdly, in the baseline analysis, we optimistically assumed no renal monitoring was required for patients on apixaban based on the subgroup analysis of ARISTOTLE [<xref ref-type="bibr" rid="pone.0157129.ref044">44</xref>] which may not be the case in real clinical practice. The subgroup analysis was pre-specified for patients with impaired renal function and showed that apixaban was more effective than warfarin in preventing stroke or systemic embolism and reducing mortality, irrespective of renal function. Considering the median age of 78.9 years in this cohort of patients, we analysed two other scenariosâ€”assuming 50% and 100% of patients will have their renal function evaluated annually, respectively, whilst on apixaban. Both scenarios show that the frequency of renal monitoring had very limited impact on the ICERs (USD 7,270 and USD 7,482 per QALY saved respectively) therefore baseline conclusions remains robust. Fourthly, treatment attributes such as convenience of drug administration, food and drug interaction were not included in this model, which may underestimate the benefits of apixaban. Lastly, the estimate for acute event cost per episode was restricted to general ward charges only and the costs of emergency and intensive care or rehabilitation have not been included. These would have led to underestimates of event related costs for both groups.</p>
</sec>
</sec>
<sec id="sec026" sec-type="conclusions">
<title>Conclusion</title>
<p>In conclusion, the current comprehensive modeling assessment based on real-life, local clinical, economic evidence and ARISTOTLE trial, demonstrate that apixaban is a cost-effective alternative against warfarin for the prevention of stroke and bleeding events in Chinese patients with NVAF. Our results suggest that apixaban is relatively more favourable in terms of health benefits and incremental cost.</p>
</sec>
<sec id="sec027">
<title>Supporting Information</title>
<supplementary-material id="pone.0157129.s001" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0157129.s001" xlink:type="simple">
<label>S1 File</label>
<caption>
<title/>
<p><bold>Figure A. Schematic representation of Markov model.</bold> NVAF: non-valvular atrial fibrillation. <bold>Figure B. Health states transitions from NVAF.</bold> CRNM Bleed: Clinically relevant non-major bleed; ICH: Intracerebral haemorrhage; NVAF: Non-valvular atrial fibrillation; NVAF without original anticoagulation: patients with NVAF who discontinue the initially assigned anticoagulation treatment but have not yet experienced any of the events including ischaemic stroke, haemorrhagic stroke, myocardial infarction, systematic embolism or death. <bold>Table A. Base-case and sensitivity analyses inputs for clinical events, deaths, post-event treatment and anticoagulation management. Table B. Base-case and sensitivity analyses inputs for utility and cost. Table C. The ICD-9 codes (diagnosis codes unless other specified) used in this study. Supplemental References.</bold></p>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<p>We thank our colleague in the Department of Pharmacology and Pharmacy of the University of Hong Kongâ€“Dr. Shweta Anand for literature search and review; and Ms. Lisa Wong for the proofreading our manuscript.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0157129.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Camm</surname> <given-names>AJ</given-names></name>, <name name-style="western"><surname>Kirchhof</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Lip</surname> <given-names>GYH</given-names></name>, <name name-style="western"><surname>Schotten</surname> <given-names>U</given-names></name>, <name name-style="western"><surname>Savelieva</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Ernst</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)</article-title>. <source>European Heart Journal</source>. <year>2010</year>;<volume>31</volume>(<issue>19</issue>):<fpage>2369</fpage>â€“<lpage>429</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/eurheartj/ehq278" xlink:type="simple">10.1093/eurheartj/ehq278</ext-link></comment> <object-id pub-id-type="pmid">20802247</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tse</surname> <given-names>HF</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>YJ</given-names></name>, <name name-style="western"><surname>Ahmed Ai-Abdullah</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Pizarro-Borromeo</surname> <given-names>AB</given-names></name>, <name name-style="western"><surname>Chiang</surname> <given-names>CE</given-names></name>, <name name-style="western"><surname>Krittayaphong</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Stroke prevention in atrial fibrillationâ€”an Asian stroke perspective</article-title>. <source>Heart rhythm: the official journal of the Heart Rhythm Society</source>. <year>2013</year>;<volume>10</volume>(<issue>7</issue>):<fpage>1082</fpage>â€“<lpage>8</lpage>.</mixed-citation></ref>
<ref id="pone.0157129.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boccuzzi</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Martin</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Stephenson</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kreilick</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Fernandes</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Beaulieu</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed</article-title>. <source>Current medical research and opinion</source>. <year>2009</year>;<volume>25</volume>(<issue>12</issue>):<fpage>2853</fpage>â€“<lpage>64</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1185/03007990903196422" xlink:type="simple">10.1185/03007990903196422</ext-link></comment> <object-id pub-id-type="pmid">19916729</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>De Caterina</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Husted</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Wallentin</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Andreotti</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Arnesen</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Bachmann</surname> <given-names>F</given-names></name>, <etal>et al</etal>. <article-title>Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosisâ€”Task Force on Anticoagulants in Heart Disease</article-title>. <source>Thrombosis and haemostasis</source>. <year>2013</year>;<volume>110</volume>(<issue>6</issue>):<fpage>1087</fpage>â€“<lpage>107</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1160/TH13-06-0443" xlink:type="simple">10.1160/TH13-06-0443</ext-link></comment> <object-id pub-id-type="pmid">24226379</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Holbrook</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Pereira</surname> <given-names>JA</given-names></name>, <name name-style="western"><surname>Labiris</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>McDonald</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Douketis</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Crowther</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Systematic overview of warfarin and its drug and food interactions</article-title>. <source>Archives of internal medicine</source>. <year>2005</year>;<volume>165</volume>(<issue>10</issue>):<fpage>1095</fpage>â€“<lpage>106</lpage>. <object-id pub-id-type="pmid">15911722</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Granger</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Alexander</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>McMurray</surname> <given-names>JJV</given-names></name>, <name name-style="western"><surname>Lopes</surname> <given-names>RD</given-names></name>, <name name-style="western"><surname>Hylek</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Hanna</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Apixaban versus Warfarin in Patients with Atrial Fibrillation</article-title>. <source>New Engl J Med</source>. <year>2011</year>;<volume>365</volume>(<issue>11</issue>):<fpage>981</fpage>â€“<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1056/NEJMoa1107039" xlink:type="simple">10.1056/NEJMoa1107039</ext-link></comment> <object-id pub-id-type="pmid">21870978</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Goto</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Zhu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Oh</surname> <given-names>BH</given-names></name>, <name name-style="western"><surname>Wojdyla</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Aylward</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial</article-title>. <source>American heart journal</source>. <year>2014</year>;<volume>168</volume>(<issue>3</issue>):<fpage>303</fpage>â€“<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.ahj.2014.06.005" xlink:type="simple">10.1016/j.ahj.2014.06.005</ext-link></comment> <object-id pub-id-type="pmid">25173541</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stevanovic</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Pompen</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Le</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Rozenbaum</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Tieleman</surname> <given-names>RG</given-names></name>, <name name-style="western"><surname>Postma</surname> <given-names>MJ</given-names></name>. <article-title>Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands</article-title>. <source>Plos One</source>. <year>2014</year>;<volume>9</volume>(<issue>8</issue>):<fpage>e103974</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0103974" xlink:type="simple">10.1371/journal.pone.0103974</ext-link></comment> <object-id pub-id-type="pmid">25093723</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lanitis</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Kongnakorn</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Jacobson</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>De Geer</surname> <given-names>A</given-names></name>. <article-title>Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation</article-title>. <source>Thrombosis research</source>. <year>2014</year>;<volume>134</volume>(<issue>2</issue>):<fpage>278</fpage>â€“<lpage>87</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.thromres.2014.05.027" xlink:type="simple">10.1016/j.thromres.2014.05.027</ext-link></comment> <object-id pub-id-type="pmid">24935675</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dorian</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Kongnakorn</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Phatak</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Rublee</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Kuznik</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lanitis</surname> <given-names>T</given-names></name>, <etal>et al</etal>. <article-title>Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation</article-title>. <source>Eur Heart J</source>. <year>2014</year>;<volume>35</volume>(<issue>28</issue>):<fpage>1897</fpage>â€“<lpage>906</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/eurheartj/ehu006" xlink:type="simple">10.1093/eurheartj/ehu006</ext-link></comment> <object-id pub-id-type="pmid">24513791</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ademi</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Pasupathi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Liew</surname> <given-names>D</given-names></name>. <article-title>Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia</article-title>. <source>European journal of preventive cardiology</source>. <year>2015</year>;<volume>22</volume>(<issue>3</issue>):<fpage>344</fpage>â€“<lpage>53</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/2047487313514019" xlink:type="simple">10.1177/2047487313514019</ext-link></comment> <object-id pub-id-type="pmid">24281250</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lee</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Mullin</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Blazawski</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Coleman</surname> <given-names>CI</given-names></name>. <article-title>Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation</article-title>. <source>Plos One</source>. <year>2012</year>;<volume>7</volume>(<issue>10</issue>):<fpage>e47473</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0047473" xlink:type="simple">10.1371/journal.pone.0047473</ext-link></comment> <object-id pub-id-type="pmid">23056642</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chiang</surname> <given-names>CE</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>KL</given-names></name>, <name name-style="western"><surname>Lip</surname> <given-names>GY</given-names></name>. <article-title>Stroke prevention in atrial fibrillation: an Asian perspective</article-title>. <source>Thrombosis and haemostasis</source>. <year>2014</year>;<volume>111</volume>(<issue>5</issue>):<fpage>789</fpage>â€“<lpage>97</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1160/TH13-11-0948" xlink:type="simple">10.1160/TH13-11-0948</ext-link></comment> <object-id pub-id-type="pmid">24500243</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>January</surname> <given-names>CT</given-names></name>, <name name-style="western"><surname>Wann</surname> <given-names>LS</given-names></name>, <name name-style="western"><surname>Alpert</surname> <given-names>JS</given-names></name>, <name name-style="western"><surname>Calkins</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Cigarroa</surname> <given-names>JE</given-names></name>, <name name-style="western"><surname>Cleveland</surname> <given-names>JC</given-names> <suffix>Jr.</suffix></name>, <etal>et al</etal>. <article-title>2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society</article-title>. <source>Circulation</source>. <year>2014</year>;<volume>130</volume>(<issue>23</issue>):<fpage>2071</fpage>â€“<lpage>104</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIR.0000000000000040" xlink:type="simple">10.1161/CIR.0000000000000040</ext-link></comment> <object-id pub-id-type="pmid">24682348</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lip</surname> <given-names>GY</given-names></name>, <name name-style="western"><surname>Kongnakorn</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Phatak</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Kuznik</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Lanitis</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>LZ</given-names></name>, <etal>et al</etal>. <article-title>Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation</article-title>. <source>Clinical therapeutics</source>. <year>2014</year>;<volume>36</volume>(<issue>2</issue>):<fpage>192</fpage>â€“<lpage>210.e20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.clinthera.2013.12.011" xlink:type="simple">10.1016/j.clinthera.2013.12.011</ext-link></comment> <object-id pub-id-type="pmid">24508420</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref016"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">The Government of Hong Kong Special Administrative Region. Hong Kong the facts: public health 2013 [cited 2014 September 22nd]. Available: <ext-link ext-link-type="uri" xlink:href="http://www.gov.hk/en/about/abouthk/factsheets/docs/public_health.pdf" xlink:type="simple">http://www.gov.hk/en/about/abouthk/factsheets/docs/public_health.pdf</ext-link>.</mixed-citation></ref>
<ref id="pone.0157129.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Connolly</surname> <given-names>SJ</given-names></name>, <name name-style="western"><surname>Pogue</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Eikelboom</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Flaker</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Commerford</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Franzosi</surname> <given-names>MG</given-names></name>, <etal>et al</etal>. <article-title>Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>118</volume>(<issue>20</issue>):<fpage>2029</fpage>â€“<lpage>37</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCULATIONAHA.107.750000" xlink:type="simple">10.1161/CIRCULATIONAHA.107.750000</ext-link></comment> <object-id pub-id-type="pmid">18955670</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Reynolds</surname> <given-names>MW</given-names></name>, <name name-style="western"><surname>Fahrbach</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hauch</surname> <given-names>O</given-names></name>, <name name-style="western"><surname>Wygant</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Estok</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Cella</surname> <given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis</article-title>. <source>Chest</source>. <year>2004</year>;<volume>126</volume>(<issue>6</issue>):<fpage>1938</fpage>â€“<lpage>45</lpage>. <object-id pub-id-type="pmid">15596696</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Claassen</surname> <given-names>DO</given-names></name>, <name name-style="western"><surname>Kazemi</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Zubkov</surname> <given-names>AY</given-names></name>, <name name-style="western"><surname>Wijdicks</surname> <given-names>EF</given-names></name>, <name name-style="western"><surname>Rabinstein</surname> <given-names>AA</given-names></name>. <article-title>Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage</article-title>. <source>Arch Neurol</source>. <year>2008</year>;<volume>65</volume>(<issue>10</issue>):<fpage>1313</fpage>â€“<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/archneur.65.10.1313" xlink:type="simple">10.1001/archneur.65.10.1313</ext-link></comment> <object-id pub-id-type="pmid">18852344</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sabir</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Khavandi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Brownrigg</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Camm</surname> <given-names>AJ</given-names></name>. <article-title>Oral anticoagulants for Asian patients with atrial fibrillation</article-title>. <source>Nat Rev Cardiol</source>. <year>2014</year>;<volume>11</volume>(<issue>5</issue>):<fpage>290</fpage>â€“<lpage>303</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nrcardio.2014.22" xlink:type="simple">10.1038/nrcardio.2014.22</ext-link></comment> <object-id pub-id-type="pmid">24614113</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ho</surname> <given-names>JCS</given-names></name>, <name name-style="western"><surname>Chang</surname> <given-names>AM</given-names></name>, <name name-style="western"><surname>Yan</surname> <given-names>BP</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Lam</surname> <given-names>YY</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>VWY</given-names></name>. <article-title>Dabigatran Compared With Warfarin for Stroke Prevention With Atrial Fibrillation: Experience in Hong Kong</article-title>. <source>Clinical cardiology</source>. <year>2012</year>;<volume>35</volume>(<issue>12</issue>):<fpage>E40</fpage>â€“<lpage>5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/clc.22069" xlink:type="simple">10.1002/clc.22069</ext-link></comment> <object-id pub-id-type="pmid">23108916</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sullivan</surname> <given-names>PW</given-names></name>, <name name-style="western"><surname>Slejko</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Sculpher</surname> <given-names>MJ</given-names></name>, <name name-style="western"><surname>Ghushchyan</surname> <given-names>V</given-names></name>. <article-title>Catalogue of EQ-5D scores for the United Kingdom</article-title>. <source>Medical decision making: an international journal of the Society for Medical Decision Making</source>. <year>2011</year>;<volume>31</volume>(<issue>6</issue>):<fpage>800</fpage>â€“<lpage>4</lpage>.</mixed-citation></ref>
<ref id="pone.0157129.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gage</surname> <given-names>BF</given-names></name>, <name name-style="western"><surname>Cardinalli</surname> <given-names>AB</given-names></name>, <name name-style="western"><surname>Owens</surname> <given-names>DK</given-names></name>. <article-title>The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life</article-title>. <source>Archives of internal medicine</source>. <year>1996</year>;<volume>156</volume>(<issue>16</issue>):<fpage>1829</fpage>â€“<lpage>36</lpage>. <object-id pub-id-type="pmid">8790077</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref024"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013 [cited 2015 July 7th]. Available: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/article/pmg9/chapter/Foreword" xlink:type="simple">https://www.nice.org.uk/article/pmg9/chapter/Foreword</ext-link>.</mixed-citation></ref>
<ref id="pone.0157129.ref025"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Hong Kong Hospital Authority. Hospital Authority Ordinance (Chapter 113): Revisons to list of charges 2013 [cited 2014 October 20th]. Available: <ext-link ext-link-type="uri" xlink:href="http://www.ha.org.hk/visitor/ha_visitor_index.asp?Content_ID=10045&amp;Lang=ENG" xlink:type="simple">http://www.ha.org.hk/visitor/ha_visitor_index.asp?Content_ID=10045&amp;Lang=ENG</ext-link>.</mixed-citation></ref>
<ref id="pone.0157129.ref026"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Hong Kong Government Gazette. Provison for Public Chargesâ€”Non-Eligible Persons 2003 [cited 2014 September 22th]. Available: <ext-link ext-link-type="uri" xlink:href="https://www.ha.org.hk/haho/ho/cs/207298en.pdf" xlink:type="simple">https://www.ha.org.hk/haho/ho/cs/207298en.pdf</ext-link>.</mixed-citation></ref>
<ref id="pone.0157129.ref027"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">The World Bank. Hong Kong GDP per capita 1960â€“2014 [cited 2014 November 26th]. Available: <ext-link ext-link-type="uri" xlink:href="http://www.tradingeconomics.com/hong-kong/gdp-per-capita" xlink:type="simple">http://www.tradingeconomics.com/hong-kong/gdp-per-capita</ext-link>.</mixed-citation></ref>
<ref id="pone.0157129.ref028"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">The Commission on Macroeconomics and Health of the World Health Organization. Macroeconomics and health: investing in health for economic development 2001 [cited 2014 Oct 10th]. Available: <ext-link ext-link-type="uri" xlink:href="http://whqlibdoc.who.int/publications/2001/924154550x.pdf" xlink:type="simple">http://whqlibdoc.who.int/publications/2001/924154550x.pdf</ext-link>.</mixed-citation></ref>
<ref id="pone.0157129.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Feigin</surname> <given-names>VL</given-names></name>, <name name-style="western"><surname>Forouzanfar</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Krishnamurthi</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Mensah</surname> <given-names>GA</given-names></name>, <name name-style="western"><surname>Connor</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Bennett</surname> <given-names>DA</given-names></name>, <etal>et al</etal>. <article-title>Global and regional burden of stroke during 1990â€“2010: findings from the Global Burden of Disease Study 2010</article-title>. <source>The Lancet</source>. <year>2014</year>;<volume>383</volume>(<issue>9913</issue>):<fpage>245</fpage>â€“<lpage>55</lpage>.</mixed-citation></ref>
<ref id="pone.0157129.ref030"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Suzman R, Beard J. Global health and ageing 2011 [cited 2015 May 10th]. Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/ageing/publications/global_health/en/" xlink:type="simple">http://www.who.int/ageing/publications/global_health/en/</ext-link>.</mixed-citation></ref>
<ref id="pone.0157129.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Morgan</surname> <given-names>CL</given-names></name>, <name name-style="western"><surname>McEwan</surname> <given-names>P</given-names></name>, <name name-style="western"><surname>Tukiendorf</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Robinson</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Clemens</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Plumb</surname> <given-names>JM</given-names></name>. <article-title>Warfarin treatment in patients with atrial fibrillation: Observing outcomes associated with varying levels of INR control</article-title>. <source>Thrombosis research</source>. <year>2009</year>;<volume>124</volume>(<issue>1</issue>):<fpage>37</fpage>â€“<lpage>41</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.thromres.2008.09.016" xlink:type="simple">10.1016/j.thromres.2008.09.016</ext-link></comment> <object-id pub-id-type="pmid">19062079</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>White</surname> <given-names>HD</given-names></name>, <name name-style="western"><surname>Gruber</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Feyzi</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Kaatz</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Tse</surname> <given-names>HF</given-names></name>, <name name-style="western"><surname>Husted</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V</article-title>. <source>Archives of internal medicine</source>. <year>2007</year>;<volume>167</volume>(<issue>3</issue>):<fpage>239</fpage>â€“<lpage>45</lpage>. <object-id pub-id-type="pmid">17296878</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ho</surname> <given-names>CW</given-names></name>, <name name-style="western"><surname>Ho</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Chan</surname> <given-names>PH</given-names></name>, <name name-style="western"><surname>Hai</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Cheung</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Yeung</surname> <given-names>CY</given-names></name>, <etal>et al</etal>. <article-title>Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control</article-title>. <source>Stroke</source>. <year>2015</year>;<volume>46</volume>(<issue>1</issue>):<fpage>23</fpage>â€“<lpage>30</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.114.006476" xlink:type="simple">10.1161/STROKEAHA.114.006476</ext-link></comment> <object-id pub-id-type="pmid">25406148</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wan</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Heneghan</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Perera</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Roberts</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Hollowell</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Glasziou</surname> <given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review</article-title>. <source>Circulation Cardiovascular quality and outcomes</source>. <year>2008</year>;<volume>1</volume>(<issue>2</issue>):<fpage>84</fpage>â€“<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/CIRCOUTCOMES.108.796185" xlink:type="simple">10.1161/CIRCOUTCOMES.108.796185</ext-link></comment> <object-id pub-id-type="pmid">20031794</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Albertsen</surname> <given-names>IE</given-names></name>, <name name-style="western"><surname>Rasmussen</surname> <given-names>LH</given-names></name>, <name name-style="western"><surname>Overvad</surname> <given-names>TF</given-names></name>, <name name-style="western"><surname>Graungaard</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Larsen</surname> <given-names>TB</given-names></name>, <name name-style="western"><surname>Lip</surname> <given-names>GY</given-names></name>. <article-title>Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis</article-title>. <source>Stroke</source>. <year>2013</year>;<volume>44</volume>(<issue>5</issue>):<fpage>1329</fpage>â€“<lpage>36</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1161/STROKEAHA.113.000883" xlink:type="simple">10.1161/STROKEAHA.113.000883</ext-link></comment> <object-id pub-id-type="pmid">23482597</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Clancy</surname> <given-names>CM</given-names></name>, <name name-style="western"><surname>Cronin</surname> <given-names>K</given-names></name>. <article-title>Evidence-based decision making: global evidence, local decisions</article-title>. <source>Health Aff (Millwood)</source>. <year>2005</year>;<volume>24</volume>(<issue>1</issue>):<fpage>151</fpage>â€“<lpage>62</lpage>.</mixed-citation></ref>
<ref id="pone.0157129.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shen</surname> <given-names>AY</given-names></name>, <name name-style="western"><surname>Yao</surname> <given-names>JF</given-names></name>, <name name-style="western"><surname>Brar</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Jorgensen</surname> <given-names>MB</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>W</given-names></name>. <article-title>Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation</article-title>. <source>Journal of the American College of Cardiology</source>. <year>2007</year>;<volume>50</volume>(<issue>4</issue>):<fpage>309</fpage>â€“<lpage>15</lpage>. <object-id pub-id-type="pmid">17659197</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref038"><label>38</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>van Asch</surname> <given-names>CJJ</given-names></name>, <name name-style="western"><surname>Luitse</surname> <given-names>MJA</given-names></name>, <name name-style="western"><surname>Rinkel</surname> <given-names>GJE</given-names></name>, <name name-style="western"><surname>van der Tweel</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Algra</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Klijn</surname> <given-names>CJM</given-names></name>. <article-title>Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis</article-title>. <source>The Lancet Neurology</source>. <year>2010</year>;<volume>9</volume>(<issue>2</issue>):<fpage>167</fpage>â€“<lpage>76</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S1474-4422(09)70340-0" xlink:type="simple">10.1016/S1474-4422(09)70340-0</ext-link></comment> <object-id pub-id-type="pmid">20056489</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref039"><label>39</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Yang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the china national stroke registry</article-title>. <source>J Stroke Cerebrovasc Dis</source>. <year>2014</year>;<volume>23</volume>(<issue>5</issue>):<fpage>1157</fpage>â€“<lpage>63</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2013.10.006" xlink:type="simple">10.1016/j.jstrokecerebrovasdis.2013.10.006</ext-link></comment> <object-id pub-id-type="pmid">24291013</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref040"><label>40</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yasaka</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Lip</surname> <given-names>GY</given-names></name>. <article-title>Impact of non-vitamin k antagonist oral anticoagulants on intracranial bleeding in Asian patients with non-valvular atrial fibrillation</article-title>. <source>Circulation Journal</source>. <year>2014</year>;<volume>78</volume>(<issue>10</issue>):<fpage>2367</fpage>â€“<lpage>72</lpage>. <object-id pub-id-type="pmid">25213003</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref041"><label>41</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chan</surname> <given-names>EW</given-names></name>, <name name-style="western"><surname>Lau</surname> <given-names>WCY</given-names></name>, <name name-style="western"><surname>Siu</surname> <given-names>CW</given-names></name>, <name name-style="western"><surname>Lip</surname> <given-names>GYH</given-names></name>, <name name-style="western"><surname>Leung</surname> <given-names>WK</given-names></name>, <name name-style="western"><surname>Anand</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study</article-title>. <source>Heart Rhythm</source>. <year>2016</year> <month>Mar</month> <day>28</day>. pii: S1547-5271(16)30150-3. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.hrthm.2016.03.049" xlink:type="simple">10.1016/j.hrthm.2016.03.049</ext-link></comment></mixed-citation></ref>
<ref id="pone.0157129.ref042"><label>42</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Witt</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Delate</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Garcia</surname> <given-names>DA</given-names></name>, <name name-style="western"><surname>Clark</surname> <given-names>NP</given-names></name>, <name name-style="western"><surname>Hylek</surname> <given-names>EM</given-names></name>, <name name-style="western"><surname>Ageno</surname> <given-names>W</given-names></name>, <etal>et al</etal>. <article-title>Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding</article-title>. <source>Archives of internal medicine</source>. <year>2012</year>;<volume>172</volume>(<issue>19</issue>):<fpage>1484</fpage>â€“<lpage>91</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/archinternmed.2012.4261" xlink:type="simple">10.1001/archinternmed.2012.4261</ext-link></comment> <object-id pub-id-type="pmid">22987143</object-id></mixed-citation></ref>
<ref id="pone.0157129.ref043"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Warren J Manning DES, Gregory YH Lip. Atrial fibrillation: Anticoagulant therapy to prevent embolization: UpToDate; 2015 [cited 2015 July 14th]. Available: <ext-link ext-link-type="uri" xlink:href="http://www.uptodate.com/contents/atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization" xlink:type="simple">http://www.uptodate.com/contents/atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization</ext-link>.</mixed-citation></ref>
<ref id="pone.0157129.ref044"><label>44</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hohnloser</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Hijazi</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Thomas</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Alexander</surname> <given-names>JH</given-names></name>, <name name-style="western"><surname>Amerena</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hanna</surname> <given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial</article-title>. <source>Eur Heart J</source>. <year>2012</year>;<volume>33</volume>(<issue>22</issue>):<fpage>2821</fpage>â€“<lpage>30</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/eurheartj/ehs274" xlink:type="simple">10.1093/eurheartj/ehs274</ext-link></comment> <object-id pub-id-type="pmid">22933567</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>